Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)

NCT03833180 is registered in ClinicalTrials.gov with VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT03833180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)
Lead sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 1
Overall status
Completed
Start date
March 14, 2019
Completion date
December 18, 2023
Enrollment
91 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myeloid leukemia, burkitt lymphoma, chronic lymphocytic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, lymphoplasmacytoid lymphoma, mantle cell lymphoma, marginal zone lymphoma, richter transformation lymphoma, t-cell non-hodgkin lymphoma, waldenstrom macroglobulinemia